How common are diabetes and prediabetes in people with atrial fibrillation?

Early Detection of Glucose Abnormalities in Atrial Fibrillation

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN18614953

Enrollment

300

Registered

2023-08-30

Start date

2018-10-18

Completion date

Unknown

Last updated

2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prevalence and prognostic importance of previously undiagnosed glucose abnormalities in patients with atrial fibrillation. Nutritional, Metabolic, Endocrine

Interventions

Study participants (individuals with atrial fibrillation undergoing electrical cardioversion) will be screened for previously undiagnosed glucose abnormalities with a glycated haemoglobin A1c (HbA1c)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Individuals with atrial fibrillation undergoing electrical cardioversion

Exclusion criteria

Exclusion criteria: 1. Diabetes mellitus type 1 2. Stage 4 or 5 CKD (GFR<30 ml/min, dialysis). 3. Malignant tumor under treatment (or metastatic cancer) with life expectancy <12 months. 4. Thyrotoxicosis 5. Acute infection and/or chronic inflammatory disease (with highly elevated inflammatory markers and/or ongoing steroid therapy). 6. Advanced COPD (e.g. treatment with steroids). 7. Conditions that complicate participation in the study as assessed by the treating physician or the study investigators.

Design outcomes

Primary

Measure	Time frame
Prevalence of previously undiagnosed diabetes and prediabetes measured at baseline using the recorded values of plasma glucose (fasting or 2-hour value after the Oral Glucose Tolerance Test) or HbA1c according to the criteria set forth by the World Health Organisation (WHO) and American Diabetes Association (ADA).	—

Secondary

Measure	Time frame
1. Recurrence of atrial fibrillation after successful electrical conversion after three months and twelve months, respectively measured using patient records 2. Recurrence of atrial fibrillation or hospitalisation for other cardiovascular disease, such as myocardial infarction, stroke, heart failure and occurrence of death over 3 years measured using patient records 3. Echocardiographic and electrocardiographic findings at inclusion measured by performing a standardised adult transthoracic echocardiography examination and by registering a standard 12-lead electrocardiogram (ECG) 4. Biochemical variables, such as troponin, pro-BNP, and markers of inflammation and fibrosis at inclusion measured by analysis of plasma venous samples in an accredited laboratory	—

Measure

Time frame

1. Recurrence of atrial fibrillation after successful electrical conversion after three months and twelve months, respectively measured using patient records 2. Recurrence of atrial fibrillation or hospitalisation for other cardiovascular disease, such as myocardial infarction, stroke, heart failure and occurrence of death over 3 years measured using patient records 3. Echocardiographic and electrocardiographic findings at inclusion measured by performing a standardised adult transthoracic echocardiography examination and by registering a standard 12-lead electrocardiogram (ECG) 4. Biochemical variables, such as troponin, pro-BNP, and markers of inflammation and fibrosis at inclusion measured by analysis of plasma venous samples in an accredited laboratory

—

Countries

Sweden

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026